NEW YORK (GenomeWeb News) – Roche today said that med fusion, a Lewisville, Texas-based clinical lab and clinical trials services firm, has been named a Roche Molecular Center of Excellence for the next five years.

As part of the designation, med fusion will offer a range of Roche's molecular technologies including the cobas 4800 V600 Mutation Test, a companion diagnostic approved by the US Food and Drug Administration last year for identifying patients who are eligible for treatment with the drug Zelboraf (vemurafenib) for inoperable or metastatic melanoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.